. 2015 Jan 20;6(1):e02227-14. doi: 10.1128/mBio.02227-14

TABLE 1 .

Summary of binding and postexposure efficacy data available for EBOV therapeutics^a

Candidate therapeutic component	Treatment modality	Therapeutic(s)	Nucleotide position based on GenBank/RefSeq entry^b	Amino acid residues of target protein	Target gene	Treatment time p.i.	Treatment success (% survival range)	Reference(s)
EK-1-mod	siRNA	Tekmira	17,396–17,418	NA	L	30 min to 6 days	66.7–100^c	8
VP24-1160-mod	siRNA	Tekmira	11,043–11,065	NA	VP24	30 min to 6 days	66.7–100^c	8
VP35-855-mod	siRNA	Tekmira	3884–3906	NA	VP35	30 min to 6 days	66.7–100^c	8
1H3 Mab	Passive immunization	ZMAB	6039–6508	1–157	GP	3–9 days	50–100^d	10, 18
2G4 Mab	Passive immunization	ZMAPP, ZMAB	7540–8039	501–676	GP	3–9 days	50–100^d^,^e	10, 12, 18
4G7 Mab	Passive immunization	ZMAPP, ZMAB	7414–7542	459–501	GP	3–9 days, 5 days	50–100^d^,^e	10, 12, 18
13C6 Mab	Passive immunization	MB-003, ZMAPP	6039–7542	1–501	GP^f	1–2 days, 5 days	66.7–100^e	11, 12, 18, 19
6D8 Mab	Passive immunization	MB-003	7204–7254	389–405	GP	1–2 days	66.7	11, 19
13F6 Mab	Passive immunization	MB-003	7240–7290	401–417	GP	1–2 days	66.7	11, 19
AVI-7537	PMO	AVI-6002	10,331–10,349	NA	VP24	30–60 min	60	9, 15
AVI-7539	PMO	AVI-6002	3133–3152	NA	VP35	30–60 min	60	9, 15

^{^a}

MAb, monoclonal antibody; NA, not applicable; p.i., postinoculation; PMO, phosphorodiamidate morpholino oligomers; siRNA, small interfering RNA. Recognition sequences for PMO and siRNA are listed in the supplemental methods.

^{^b}

siRNA positions include both sense and antisense oligonucleotide positions. Mutations specific to each are designated in Fig. 1.

^{^c}

Survival range is dependent on dosing.

^{^d}

Survival range is dependent on addition of Ad-IFN (interferon co-treatment) to treatment 1 day p.i.

^{^e}

Survival range is dependent on formulation.

^{^f}

Cross-reacts with TAFV (Tai Forest virus) and SUDV (Sudan virus) GP.